The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Artificial intelligence's potential in ophthalmology, particularly in ocular imaging, was a major focus, with debates on its ...

The recall centers on Prograf 0.5 mg capsules (lot No. 0E3353D) and Astagraf XL 0.5 mg capsules (lot No. 0R3092A), both of which carry the expiration date March 2026. Prograf is used after heart ...

READ MORE: Eye drops sold at Publix, Amazon recalled for fungal contamination The deconstructed box of 0.5 mg strength Prograf. Not all Prograf and Astagraf XL on the market have been recalled.

Subscribe here to receive future editions. There may be a new, unintended side effect linked to Novo Nordisk's blockbuster diabetes injection, Ozempic. Danish health authorities on Monday said ...

Danish health authorities on Monday said they are asking the European Union's drug regulator to review the findings of two Danish studies linking Ozempic to an increased risk of a rare vision ...

In clinical trials of Ozempic and Wegovy, nausea was reported in: 15.8 percent of those taking a 0.5 milligram (mg) dose of semaglutide 20.3 percent of those taking a 1 mg dose 44 percent of those ...

Novo Nordisk's diabetes drug Ozempic has been linked to a rare and serious eye condition that can cause sudden and irreversible vision loss, according to a new study published on medRxiv. The research ...

Novo Nordisk’s (NVO) blockbuster diabetes drug Ozempic may have a potential link with an eye condition that causes vision loss, according to a non-peer reviewed study published Thursday on medRxiv.

(Bloomberg) -- Novo Nordisk A/S’s blockbuster shot Ozempic was linked to an increased risk of a rare form of vision loss in a study that backs up Harvard University research published earlier this ...

Please note that Novo Nordisk’s once-weekly subcutaneous diabetes injection, Ozempic, is already approved in 0.25 mg, 0.5 mg, 1 mg and 2 mg doses for treating T2D mellitus in adults, adjunct to ...